What does this research mean for the field?

Fenofibrate can induce severe rhabdomyolysis complicated by dialysis-requiring acute kidney injury in older patients with chronic kidney disease, even in the absence of classic symptoms such as myalgia and dark urine. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To report a case of fenofibrate-induced rhabdomyolysis leading to severe, dialysis-dependent acute kidney injury presenting without classic muscle symptoms in an older patient with chronic kidney disease.

August 23, 2026MedicineOpen Access

Fenofibrate-associated rhabdomyolysis complicated by dialysis-requiring acute kidney injury presenting with atypical clinical manifestations

View Full Paper

Ask AI

Bookmark

Authors

YFYumei Fang YJYan Jiang

Discussion

Member takes

Overview

Case report reveals atypical fenofibrate-associated rhabdomyolysis causing acute kidney injury in chronic kidney disease, highlighting the need for renal dose adjustment and monitoring.

Key Points

To report a case of fenofibrate-induced rhabdomyolysis leading to severe, dialysis-dependent acute kidney injury presenting without classic muscle symptoms in an older patient with chronic kidney disease.
Clinical and laboratory assessment of a 70-year-old male with preexisting chronic kidney disease who developed acute renal failure following initiation of micronized fenofibrate.
Treatment involving drug cessation, intravenous fluids, electrolyte management, and intermittent hemodialysis with long-term follow-up.
Serum creatinine increased markedly from ~130 μmol/L to 1,132–1,202 μmol/L alongside a peak creatine kinase of 28,831 U/L and serum myoglobin of 915 ng/mL without myalgia or dark urine.
Following drug discontinuation and 5 weeks of intermittent hemodialysis, kidney function improved, with serum creatinine decreasing to 157 μmol/L and normal muscle enzymes at 8-month follow-up.

Cite This Study

Fang et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae407677a3411444726d https://doi.org/10.1097/md.0000000000050337

View Full Paper

Ask AI

Bookmark

August 23, 2026MedicineOpen Access

Fenofibrate-associated rhabdomyolysis complicated by dialysis-requiring acute kidney injury presenting with atypical clinical manifestations

View Full Paper

Ask AI

Bookmark

Authors

YFYumei Fang YJYan Jiang

Discussion

Member takes

Overview

Case report reveals atypical fenofibrate-associated rhabdomyolysis causing acute kidney injury in chronic kidney disease, highlighting the need for renal dose adjustment and monitoring.

Key Points

To report a case of fenofibrate-induced rhabdomyolysis leading to severe, dialysis-dependent acute kidney injury presenting without classic muscle symptoms in an older patient with chronic kidney disease.
Clinical and laboratory assessment of a 70-year-old male with preexisting chronic kidney disease who developed acute renal failure following initiation of micronized fenofibrate.
Treatment involving drug cessation, intravenous fluids, electrolyte management, and intermittent hemodialysis with long-term follow-up.
Serum creatinine increased markedly from ~130 μmol/L to 1,132–1,202 μmol/L alongside a peak creatine kinase of 28,831 U/L and serum myoglobin of 915 ng/mL without myalgia or dark urine.
Following drug discontinuation and 5 weeks of intermittent hemodialysis, kidney function improved, with serum creatinine decreasing to 157 μmol/L and normal muscle enzymes at 8-month follow-up.

Cite This Study

Fang et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae407677a3411444726d https://doi.org/10.1097/md.0000000000050337

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark